benapenem / Sihuan Pharmaceutical - LARVOL DELTA

Novel Antimicrobial Agents for Gram-Negative Pathogens. (PubMed, Antibiotics (Basel)) - "There are new antimicrobials that became commercially available during the last five years, namely, cefiderocol, imipenem-cilastatin-relebactam, eravacycline, omadacycline, and plazomicin. Furthermore, other agents are in advanced development, having reached phase 3 clinical trials, namely, aztreonam-avibactam, cefepime-enmetazobactam, cefepime-taniborbactam, cefepime-zidebactam, sulopenem, tebipenem, and benapenem. In this present review, we critically discuss the characteristics of the above-mentioned antimicrobials, their pharmacokinetic/pharmacodynamic properties and the current clinical data."

Gram negative • Journal • Review • Infectious Disease

Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment. (PubMed, Eur J Clin Pharmacol) - "No adjustment to benapenem dosing is needed in patients with mild to moderate renal impairment."

Journal • PK/PD data • Renal Disease

A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (clinicaltrials.gov) - P2/3; N=112; Completed; Sponsor: Sihuan Pharmaceutical Holdings Group Ltd.

Clinical • New P2/3 trial • Infectious Disease • Nephrology • Renal Calculi